197 related articles for article (PubMed ID: 23681804)
1. DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.
Xue YZ; Wu TL; Wu YM; Sheng YY; Wei ZQ; Lu YF; Yu LH; Li JP; Li ZS
Tumour Biol; 2013 Oct; 34(5):2857-61. PubMed ID: 23681804
[TBL] [Abstract][Full Text] [Related]
2. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
Zhao L; Cui Q; Lu Z; Chen J
Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
[TBL] [Abstract][Full Text] [Related]
3. Expression of UbcH10 in pancreatic ductal adenocarcinoma and its correlation with prognosis.
Zhao ZK; Wu WG; Chen L; Dong P; Gu J; Mu JS; Yang JH; Liu YB
Tumour Biol; 2013 Jun; 34(3):1473-7. PubMed ID: 23355337
[TBL] [Abstract][Full Text] [Related]
4. MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma.
Chen DW; Fan YF; Li J; Jiang XX
Tumour Biol; 2013 Jun; 34(3):1553-7. PubMed ID: 23400716
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma.
Lu XX; Zhang SM; Fang Y; Wang ZT; Xie JJ; Zhan Q; Deng XX; Chen H; Jin JB; Peng CH; Li HW; Shen BY
Tumour Biol; 2013 Dec; 34(6):3339-43. PubMed ID: 23749490
[TBL] [Abstract][Full Text] [Related]
7. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
8. High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma.
Wang L; Gu F; Liu CY; Wang RJ; Li J; Xu JY
Tumour Biol; 2013 Apr; 34(2):853-8. PubMed ID: 23242609
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation along with LOH, but not mutation, contributes to inactivation of DLC-1 in nasopharyngeal carcinoma.
Feng X; Ren C; Zhou W; Liu W; Zeng L; Li G; Wang L; Li M; Zhu B; Yao K; Jiang X
Mol Carcinog; 2014 Nov; 53(11):858-70. PubMed ID: 23908159
[TBL] [Abstract][Full Text] [Related]
10. Decreased circadian component Bmal1 predicts tumor progression and poor prognosis in human pancreatic ductal adenocarcinoma.
Li W; Liu L; Liu D; Jin S; Yang Y; Tang W; Gong L
Biochem Biophys Res Commun; 2016 Mar; 472(1):156-62. PubMed ID: 26915801
[TBL] [Abstract][Full Text] [Related]
11. Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance.
Xue YZ; Sheng YY; Liu ZL; Wei ZQ; Cao HY; Wu YM; Lu YF; Yu LH; Li JP; Li ZS
Tumour Biol; 2013 Apr; 34(2):895-9. PubMed ID: 23247867
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.
Xia JT; Wang H; Liang LJ; Peng BG; Wu ZF; Chen LZ; Xue L; Li Z; Li W
Pancreas; 2012 May; 41(4):629-35. PubMed ID: 22249132
[TBL] [Abstract][Full Text] [Related]
13. Low expression of TBX4 predicts poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Zong M; Meng M; Li L
Int J Mol Sci; 2011; 12(8):4953-63. PubMed ID: 21954337
[TBL] [Abstract][Full Text] [Related]
14. Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis.
Ning Z; Wang A; Liang J; Liu J; Zhou T; Yan Q; Wang Z
Int J Clin Exp Pathol; 2014; 7(5):2462-9. PubMed ID: 24966957
[TBL] [Abstract][Full Text] [Related]
15. Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma.
Liu Q; Chen J; Wang J; Amos C; Killary AM; Sen S; Wei C; Frazier ML
Mol Carcinog; 2014 Sep; 53(9):711-21. PubMed ID: 23661430
[TBL] [Abstract][Full Text] [Related]
16. Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas.
He D; Zhang YW; Zhang NN; Zhou L; Chen JN; Jiang Y; Shao CK
Med Oncol; 2015 Apr; 32(4):92. PubMed ID: 25720522
[TBL] [Abstract][Full Text] [Related]
17. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis.
Manoochehri M; Wu Y; Giese NA; Strobel O; Kutschmann S; Haller F; Hoheisel JD; Moskalev EA; Hackert T; Bauer AS
Mol Oncol; 2020 Jun; 14(6):1252-1267. PubMed ID: 32243066
[TBL] [Abstract][Full Text] [Related]
18. Overexpressing TNF-alpha in pancreatic ductal adenocarcinoma cells and fibroblasts modifies cell survival and reduces fatty acid synthesis via downregulation of sterol regulatory element binding protein-1 and activation of acetyl CoA carboxylase.
Al-Zoubi M; Chipitsyna G; Saxena S; Sarosiek K; Gandhi A; Kang CY; Relles D; Andrelsendecki J; Hyslop T; Yeo CJ; Arafat HA
J Gastrointest Surg; 2014 Feb; 18(2):257-68; discussion 268. PubMed ID: 24091913
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma.
Masugi Y; Yamazaki K; Emoto K; Effendi K; Tsujikawa H; Kitago M; Itano O; Kitagawa Y; Sakamoto M
Lab Invest; 2015 Mar; 95(3):308-19. PubMed ID: 25599535
[TBL] [Abstract][Full Text] [Related]
20. Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma.
Chen X; Yu S; Chen J; Chen X
Cancer Immunol Immunother; 2024 Jun; 73(8):149. PubMed ID: 38833018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
